Insmed Scraps Skin Plans for Lung Disease Drug as Competitors Make Headway
After a Phase 2 flop, Brinsupri exits the race to market for the chronic skin disease hidradenitis suppurativa, but other companies, including Incyte, Novartis and UCB, have recently notched clinical and regulatory victories.
Insmed Scraps Skin Plans for Lung Disease Drug as Competitors Make Headway Read More »
